Sogen Data · Datasets · 数据专题
肾透明细胞癌病例-正常对照轴数据集锦
bulk 转录组
本专题承自 Sogen Data 数据整理体系,逐条人工复核,附研究设计、样本量、平台与 GEO/PubMed 直达链接。
人源bulk 转录组
Human · Bulk RNA-seq
-
01 GSE304059 对肾透明细胞癌(ccRCC)与正常组织的RNA-seq数据进行分析,研究RBX1在肿瘤组织中的表达及其与疾病分期、预后的关系,同时探讨RBX1在体外实验中对ccRCC细胞增殖、迁移、侵袭及对靶向药物sunitinib的耐药性影响。
设计对肾透明细胞癌(ccRCC)与正常组织的RNA-seq数据进行分析,研究RBX1在肿瘤组织中的表达及其与疾病分期、预后的关系,同时探讨RBX1在体外实验中对ccRCC细胞增殖、迁移、侵袭及对靶向药物sunitinib的耐药性影响。
摘要Clear cell renal cell carcinoma (ccRCC) often exhibits drug resistance, highlight_x0002_ing the need to identify novel therapeutic targets. RING box protein 1 (RBX1), an E3 ubiquitin ligase associated with tumor progression, has an unclear role in ccRCC. This study investigated the clinical significance, molecular mech_x0002_anisms, and role of RBX1 in treatment resistance through multi-omics and functional analyses. Analysis of The Cancer Genome Atlas (TCGA) data revealed that RBX1 is overexpressed in ccRCC and is associated with advanced dis_x0002_ease stages and poor prognosis. Functional enrichment studies linked RBX1 to processes such as cytoskeletal remodeling,extracellular matrix deposition, and lipid metabolism disorders.Additionally, tumors with high RBX1 expression exhibit an immunosuppressive microenvironment characterized by increased reg_x0002_ulatory T cells (Tregs) and elevated expression of immune checkpoint markers (LAG3/Galectin-9). In vitro experiments confirmed that RBX1 promotes ccRCC proliferation, migration, and invasion while conferring resistance to the standard targeted therapy drug sunitinib. Our findings suggest that RBX1 may serve as a key driver of ccRCC invasiveness and immune suppression. These discoveries indicate that RBX1 has the potential to become a prognostic biomarker and a target for precision therapy in advanced ccRCC.
-
02 GSE3 对37例肾癌患者及其配对的正常肾上皮组织样本进行cDNA微阵列表达谱分析,比较肾癌与正常组织的基因表达差异。研究包含342个GSM记录,涵盖不同临床阶段(I-IV、M)及性别(男、女、未提供)的样本。
设计对37例肾癌患者及其配对的正常肾上皮组织样本进行cDNA微阵列表达谱分析,比较肾癌与正常组织的基因表达差异。研究包含342个GSM记录,涵盖不同临床阶段(I-IV、M)及性别(男、女、未提供)的样本。
摘要We investigated the changes in gene expression accompanying the development and progression of kidney cancer using 31,500 element complementary DNA arrays. We measured expression profiles for paired neoplastic and non-cancerous renal epithelium samples from 37 individuals. Using an experimental design optimized for factoring out technological and biological noise, and an adapted statistical test, we find 1738 differentially expressed cDNAs with an expected number of 6 false positives. Functional annotation of these genes provided views of the changes in the activities of specific biological pathways in renal cancer. Cell adhesion, signal transduction, and nucleotide metabolism were among the biological processes with a large proportion of genes overexpressed in renal cell carcinoma. Downregulated pathways in the kidney tumor cells included small molecule transport, ion homeostasis, and oxygen and radical metabolism. Our expression profiling data uncover gene expression changes shared with other epithelial tumors, as well as a unique signature for renal cell carcinoma. Expression data for the differentially expressed cDNAs are available in the web supplement (http://www.dkfz-heidelberg.de/abt0840/whuber/rcc). Keywords = renal clear cell carcinoma, kidney Keywords: other
-
03 GSE309697 对32名肾透明细胞癌患者及其正常组织进行H3K27ac和HIF2α染色质免疫沉淀测序(ChIP-seq)、ATAC-seq和RNA-seq,分析肾透明细胞癌在正常、肿瘤和转移状态下的表观遗传特征。研究包括57个独立组织样本和5个肾癌细胞系,采用ChIP-seq、ATAC-seq和RNA-seq技术,检测H3K27ac和HIF2α的染色质结合状态、染色质可及性及基因表达水平,比较肿瘤组织与正常组织的差异。
设计对32名肾透明细胞癌患者及其正常组织进行H3K27ac和HIF2α染色质免疫沉淀测序(ChIP-seq)、ATAC-seq和RNA-seq,分析肾透明细胞癌在正常、肿瘤和转移状态下的表观遗传特征。研究包括57个独立组织样本和5个肾癌细胞系,采用ChIP-seq、ATAC-seq和RNA-seq技术,检测H3K27ac和HIF2α的染色质结合状态、染色质可及性及基因表达水平,比较肿瘤组织与正常组织的差异。
摘要By generating 194 epigenomic and transcriptomic profiles datasets from 57 human tissue samples, using H3K27ac and HIF2α chromatin immunoprecipitation sequencing (ChIP-seq), ATAC-seq, and RNA-seq, we provide a comprehensive integrated characterization of clear cell renal cell carcinoma (ccRCC) across normal, tumor, and metastatic states. Our epigenomic analyses reveal insights into various aspects of ccRCC biology. First, we show that significant enhancer reprogramming (H3K27ac) and shifts in the transcription factor HIF2α cistrome and chromatin accessibility landscape occur during the transition from normal to tumor; by contrast, there areis no significant differences between localized tumors and metastatic samples. Second, we show that fetal kidney-specific developmental pathways are reactivated to drive malignancy. Third, we performed the first cistrome cistrome-wide association study (CWAS) in ccRCC, validating five established RCC risk loci and identifying six novel regions associated with RCC risk, including a significant association on 12q24 linked to the SCARB1 gene that was functionally validated. These datasets provide new perspectives on the role of developmental pathways in ccRCC tumorigenesis and metastasis, insights into epigenetic mechanisms of ccRCC heritability, and a comprehensive epigenomic atlas for the research community.
-
04 GSE40435 对101对肾透明细胞癌(ccRCC)肿瘤组织与相邻非肿瘤肾组织进行全基因组表达分析,比较两者基因表达差异。研究对象为捷克患者来源的肿瘤组织与配对的非肿瘤肾组织,采用Illumina HumanHT-12 v4芯片检测,未设置额外处理条件。
设计对101对肾透明细胞癌(ccRCC)肿瘤组织与相邻非肿瘤肾组织进行全基因组表达分析,比较两者基因表达差异。研究对象为捷克患者来源的肿瘤组织与配对的非肿瘤肾组织,采用Illumina HumanHT-12 v4芯片检测,未设置额外处理条件。
摘要We conducted whole-genome expression profiling on 101 pairs of ccRCC tumours and adjacent non-tumour renal tissue from Czech patients using the Illumina HumanHT-12 v4 Expression BeadChips to explore the molecular variations underlying the biological and clinical heterogeneity of ccRCC.
-
05 GSE86095 对肾透明细胞癌(ccRCC)肿瘤组织与相邻正常肾组织进行染色质免疫沉淀测序(ChIP-Seq)和转录组测序(RNA-Seq),检测 H3K4me3、H3K27ac、H3K27me3、ETS1、NFkB、P300、C-Jun 等组蛋白修饰和转录因子的结合情况,比较 ccRCC 肿瘤组织与正常组织的差异。
-
06 GSE337928 对127例肾透明细胞癌肿瘤组织和33例相邻正常组织进行RNA-Seq测序,评估差异转录使用和转录丰度,比较肿瘤与正常组织的转录特征差异。
设计对127例肾透明细胞癌肿瘤组织和33例相邻正常组织进行RNA-Seq测序,评估差异转录使用和转录丰度,比较肿瘤与正常组织的转录特征差异。
摘要Clear cell renal cell carcinoma (ccRCC) is characterized by transcriptional repro-gramming driven by hypoxia signaling, metabolic rewiring, and immune modulation. While gene-level analyses have defined key features of ccRCC biology, they do not capture isoform-level variation arising from alternative splicing. Differential transcript usage (DTU) represents an additional regulatory layer that may influence protein func-tion, pathway activity, and clinical outcomes, yet its role in ccRCC biology and progno-sis remains incompletely understood. We assessed differential expression in 127 ccRCC tumors and 33 normal-adjacent tissues from the Dartmouth Cancer Center co-hort, with external validation in 94 CPTAC tumors, adjusting for cell-type proportions. Formal DTU was first tested using DRIMSeq/stageR, which evaluates shifts in relative isoform proportions within genes. StageR-significant transcripts were then evaluated in a separate covariate-adjusted limma-voom transcript-abundance analysis incorpo-rating clinical and tumor microenvironment covariates. Consensus clustering of tran-script-level expression defined tumor subgroups, and Cox proportional hazards mod-eling integrated transcript-level features with clinical variables. In tumor versus normal comparisons, 1,170 transcripts passed both the formal DTU screen and the covariate-adjusted transcript-abundance criteria, mapping to canonical ccRCC pathways with distinct patterns across functional and non-functional transcript classes. Consensus clustering based on transcript-level expression identified two subgroups with distinct angiogenic profiles and significant survival differences. Cluster-level analysis revealed DTU-supported transcript-abundance changes in genes involved in cytoskeletal or-ganization (ACTB), immune processes (B2M), extracellular matrix organization (FN1, APLP2), and iron metabolism (FTH1), with protein domain alterations including the loss of actin-associated domains in ACTB and immunoglobulin-like domains in B2M. Prognostic modeling identified twelve candidate transcripts passing an exploratory se-lection threshold across repeated train-test splits and provided preliminary evidence of additional prognostic information when combined with clinical variables. External vali-dation was limited to two overlapping candidates, FGFR1 and NUCB1. Isoform-level features may serve as biomarkers and therapeutic targets in ccRCC.
-
07 GSE46699 对肾透明细胞癌患者与正常组织进行比较,分吸烟与非吸烟、肥胖与非肥胖组,采集肿瘤和邻近正常组织的总RNA,采用微阵列分析,比较吸烟或肥胖相关ccRCC中肿瘤与正常组织的分子差异。
设计对肾透明细胞癌患者与正常组织进行比较,分吸烟与非吸烟、肥胖与非肥胖组,采集肿瘤和邻近正常组织的总RNA,采用微阵列分析,比较吸烟或肥胖相关ccRCC中肿瘤与正常组织的分子差异。
摘要Both cigarette smoking and obesity have been implicated in increased risk of clear cell renal cell carcinoma (ccRCC); however, there are limited data regarding the molecular mechanisms that underlie these associations. We used a multi-stage design to identify and validate specific molecular targets that are associated with smoking or obesity-related ccRCC.
-
08 GSE17818 对人类肾癌清样细胞亚型组织与正常肾组织的基因表达进行分析,关联其体细胞突变状态,比较两种组织类型的基因表达差异。
设计对人类肾癌清样细胞亚型组织与正常肾组织的基因表达进行分析,关联其体细胞突变状态,比较两种组织类型的基因表达差异。
摘要Systematic somatic mutation screening of 4000 genes in human clear cell renal cell carcinoma. Information on corresponding somatic mutations in each sample can be found at http://www.sanger.ac.uk/genetics/CGP/Studies/.
-
09 GSE151428 收集 107 例肾透明细胞癌(clear cell renal cell carcinoma, ccRCC)患者肿瘤组织与配对癌旁组织进行 bulk RNA 表达谱分析,采用 TruSeq RNA Library Preparation Kit v2 和 TruSeq Small RNA Library Preparation Kit 实施 RNA-Seq 与 miRNA-Seq 测序,比较 ccRCC 肿瘤组织与癌旁组织的基因表达差异。
-
10 GSE289907 对肾透明细胞癌(ccRCC)患者进行 RNA 测序,比较肿瘤与正常组织的分子特征,同时分析非洲(AFR)和欧洲(EUR)基因相似性群体的差异。研究对象为 59 名匹配的黑人(B)和白人(W)患者,采集其肿瘤和正常组织样本,通过估计遗传相似性至 AFR 和 EUR 1000 Genomes 群体进行比较,最终扩展为 254 名患者(79 AFR,175 EUR)的队列,分析 VHL 突变频率、3p 缺失、分子亚型分布及通路富集差异。
设计对肾透明细胞癌(ccRCC)患者进行 RNA 测序,比较肿瘤与正常组织的分子特征,同时分析非洲(AFR)和欧洲(EUR)基因相似性群体的差异。研究对象为 59 名匹配的黑人(B)和白人(W)患者,采集其肿瘤和正常组织样本,通过估计遗传相似性至 AFR 和 EUR 1000 Genomes 群体进行比较,最终扩展为 254 名患者(79 AFR,175 EUR)的队列,分析 VHL 突变频率、3p 缺失、分子亚型分布及通路富集差异。
摘要Self-reported Black (B) individuals remain underrepresented in molecular studies of clear cell renal cell carcinoma (ccRCC) relative to White (W) individuals. We performed whole-exome and transcriptome sequencing on paired tumor and normal samples from 59 matched B and W patients undergoing nephrectomy for localized ccRCC, comparing molecular differences by estimated genetic similarity to African (AFR) and European (EUR) 1000 Genomes groups. We validated our findings with a propensity-matched subset of TCGA, yielding a final cohort of 254 patients (79 AFR, 175 EUR) with similar baseline clinical variables. Significant differences emerged in VHL mutation frequency (AFR: 23.4%, EUR: 57.5%; FDR = 0.0029) and chromosome 3p deletions (AFR: 59.2%, EUR: 82.6%; FDR = 0.086). Transcriptomic analyses identified 34 genes associated with genetic similarity, and gene set enrichment revealed inflammatory (interferon gamma/alpha, allograft rejection), proliferative (E2F targets, G2M checkpoint), and metabolic (bile acid, fatty acid, glycolysis, MTORC1, peroxisome) pathway enrichment in EUR. We also observed differences in ccRCC molecular subtype distribution, with “Proliferative” and “Angio/Stromal” subtypes more common in AFR (p = 0.018). Importantly, differential subtype membership explained most group-level differences. These results link EUR and AFR genetic similarity to distinct ccRCC molecular subtypes, underscoring the importance of molecular classifiers in disease stratification and the need to include diverse populations in molecular studies to improve our understanding and treatment of ccRCC.
-
11 GSE151419 本研究比较了肾透明细胞癌(ccRCC)肿瘤组织与正常相邻肾组织的miRNA表达,采用RNA测序技术分析58例ccRCC样本和17例正常样本,旨在识别亚型特异性miRNA标志物。
设计本研究比较了肾透明细胞癌(ccRCC)肿瘤组织与正常相邻肾组织的miRNA表达,采用RNA测序技术分析58例ccRCC样本和17例正常样本,旨在识别亚型特异性miRNA标志物。
摘要Renal cell carcinoma (RCC) is one of the most common cancers worldwide with nearly non-symptomatic course till advanced stage of disease. RCC can be distinguished into three subtypes: papillary (pRCC), chromophobe (chRCC) and clear cell renal cell carcinoma (ccRCC) representing up to 75% of all RCC cases. Detection and RCC monitoring tools are limited to standard imaging techniques, in combination with non-RCC specific morphological and biochemical read-outs. RCC subtype identification relays mainly on results of pathological examination of tumor slides. Molecular, clinically applicable and ideally non-invasive tools aiding RCC management are still non-existent, although molecular characterization of RCC is relatively advanced. Hence many research efforts concentrate on identification of molecular markers that will assist with RCC sub-classification and monitoring. Due to stability and tissue-specificity miRNAs are promising candidates for such biomarkers. Here we performed a meta-analysis study, utilized seven available NGS and seven microarray RCC studies in order to identify subtype-specific expression of miRNAs. We concentrated on four potentially oncocytoma-specific miRNAs (miRNA-424-5p, miRNA-146b-5p, miRNA-183-5p, miRNA-218-5p), two pRCC (miRNA-127-3p, miRNA-139-5p) and eight ccRCC specific miRNAs (miRNA-200c-3p, miRNA-362-5p, miRNA-363-3p and miRNA-204-5p, 21-5p, miRNA-224-5p, miRNA-155-5p, miRNA-210-3p) and validated their expression in an independent sample set. Additionally, we found ccRCC-specific miRNAs to be differentially expressed in ccRCC Fuhrman grades and identified alterations in their isoform composition in tumor tissue. Our results revealed that changes in expression of selected miRNA might be potentially utilized as a tool aiding ccRCC subclass discrimination and propose a miRNA panel aiding RCC subtype distinction.
-
12 GSE325575 对肾透明细胞癌肿瘤组织及相邻正常肾组织进行RNA测序,比较两者在糖基化相关基因和糖原基因表达上的差异。
设计对肾透明细胞癌肿瘤组织及相邻正常肾组织进行RNA测序,比较两者在糖基化相关基因和糖原基因表达上的差异。
摘要Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and is characterized by altered metabolism, immune remodeling, and aberrant glycosylation. Although glycosylation regulates tumor-cell signaling, adhesion, angiogenesis, and immune recognition, its relationship with the ccRCC immune microenvironment remains incompletely defined. Here, we analyzed RNA-sequencing profiles from ccRCC tumors and adjacent normal kidney tissues. Glycan-related genes and 380 glycogenes involved in glycan biosynthesis distinguished ccRCC tumors from normal tissues and revealed altered glycosidase, N-glycan, O-glycan, and glycosyltransferase pathways. CIBERSORTx analysis showed distinct immune cell distributions in tumors, and Spearman correlation analysis linked glycosylation pathway activity with immune cell abundance. Glycogene expression further classified ccRCC tumors into two subtypes with different immune signatures, Siglec expression patterns, and overall survival. Our results underscore the importance of targeting cancer-associated changes in glycosylation machinery using novel strategies to improve the specificity and efficacy of cancer therapeutics in ccRCC.
-
13 GSE16449 对48例肾透明细胞癌肿瘤样本及18例对应正常肾组织样本进行基因表达分析,使用修改后的商业参考RNA(Perou CM等,2000)作为对照,比较肿瘤与正常组织的基因表达差异。
设计对48例肾透明细胞癌肿瘤样本及18例对应正常肾组织样本进行基因表达分析,使用修改后的商业参考RNA(Perou CM等,2000)作为对照,比较肿瘤与正常组织的基因表达差异。
摘要Renal cell carcinoma (RCC) tumors express varying gene profiles, dependent on varying genetic events. Here we analyzed a series of ccRCC tumors to show that two subtypes of ccRCC exist based on their molecular signature. These subtypes (ccA and ccB) are identifiable by a robust set of genes representing distinct biological pathways and are correlated with patient survival post-nephrectomy. Keywords: Patient sample study
-
15 GSE26574 对肾透明细胞癌患者来源的正常组织与肿瘤组织进行表达分析,比较两组基因表达差异。
设计对肾透明细胞癌患者来源的正常组织与肿瘤组织进行表达分析,比较两组基因表达差异。
摘要Fumarate hydratase (FH) mutation causes hereditary type 2 papillary renal cell carcinoma (HLRCC, Hereditary Leiomyomatosis and Renal Cell Cancer (MM ID # 605839)). The main effect of FH mutation is fumarate accumulation. The current paradigm posits that the main consequence of fumarate accumulation is HIF-a stabilization. Paradoxically, FH mutation differs from other HIF-a stabilizing mutations, such as VHL and SDH mutations, in its associated tumor types. We identified that fumarate can directly up-regulate antioxidant response element (ARE)-controlled genes. We demonstrated that AKR1B10 is an ARE-controlled gene and is up-regulated upon FH knockdown as well as in FH-null cell lines. AKR1B10 overexpression is also a prominent feature in both hereditary and sporadic PRCC2. This phenotype better explains the similarities between hereditary and sporadic PRCC2.
-
16 GSE68417 将高阶清样肾细胞癌(Fuhrman 3/4,n=16)与低阶清样肾细胞癌(Fuhrman 1/2,n=13)的基因表达数据分别与正常肾组织(n=14)及良性肾病样本(n=6)进行比较,研究对象包括肾肿瘤组织、正常肾组织及良性肾病组织,检测方式为基于 Affymetrix GeneChip 平台的基因表达分析,主要比较高阶与低阶清样肾细胞癌与正常肾组织、良性肾病样本的基因表达差异。
设计将高阶清样肾细胞癌(Fuhrman 3/4,n=16)与低阶清样肾细胞癌(Fuhrman 1/2,n=13)的基因表达数据分别与正常肾组织(n=14)及良性肾病样本(n=6)进行比较,研究对象包括肾肿瘤组织、正常肾组织及良性肾病组织,检测方式为基于 Affymetrix GeneChip 平台的基因表达分析,主要比较高阶与低阶清样肾细胞癌与正常肾组织、良性肾病样本的基因表达差异。
摘要Patients undergoing either partial or radical nephrectomy at William Beaumont Hospital (Royal Oak, MI) were consented prior to surgery with local IRB oversight. Samples were collected at time of surgery and stored at -80°C according to CAP (College of American Pathologist)-accredited standard operating procedures. Disease pathology of frozen samples was validated with hematoxylin and eosin stained tissue sections from adjacently collected formalin fixed paraffin embedded tissue. The objective of this study was to examine the gene expression patterns of clear cell carcinoma in relation to adjacent normal kidney as well as other benign kidney conditions. In particular, the goal was to identify gene expression that could differentiate high grade ccRCC from low grade ccRCC.
-
17 GSE7367 从6名患者的肾肿瘤组织及其相邻非肿瘤组织中获取匹配样本的基因表达谱,使用定制的cDNA微阵列平台进行检测,每组样本包含4次重复测量,通过荧光标记的cDNA靶标与微阵列杂交,比较肿瘤组织与非肿瘤组织的转录特征。
设计从6名患者的肾肿瘤组织及其相邻非肿瘤组织中获取匹配样本的基因表达谱,使用定制的cDNA微阵列平台进行检测,每组样本包含4次重复测量,通过荧光标记的cDNA靶标与微阵列杂交,比较肿瘤组织与非肿瘤组织的转录特征。
摘要The clear cell subtype of renal cell carcinoma (RCC) is the most lethal and prevalent cancer of the urinary system. To investigate the molecular changes associated with malignant transformation in clear cell RCC, the gene expression profiles of matched samples of tumor and adjacent non-neoplastic tissue were obtained from 6 patients. A custom-built cDNA microarray platform was used, comprising 2,292 probes that map to exons of genes and 822 probes for noncoding RNAs mapping to intronic regions. Intronic transcription was detected in all normal and neoplastic renal tissues. A subset of 55 transcripts was significantly down-regulated in clear cell RCC relative to the matched non-tumor tissue as determined by a combination of two statistical tests and leave-one-out patient cross-validation. Among the down-regulated transcripts, 49 mapped to untranslated or coding exons and 6 were intronic relative to known exons of protein-coding genes. Lower levels of expression of SIN3B, TRIP3, SYNJ2BP and NDE1 (p < 0.02), and of intronic transcripts derived from SND1 and ACTN4 loci (p < 0.05), were confirmed in clear cell RCC by Real-time RT-PCR. A subset of 25 transcripts was deregulated in additional 6 non-clear cell RCC samples, pointing to common transcriptional alterations in RCC irrespective of the histological subtype or differentiation state of the tumor. Our results indicate a novel set of tumor suppressor gene candidates, including noncoding intronic RNAs, which may play a significant role in malignant transformations of normal renal cells. Keywords: Disease state analysis
-
18 GSE17816 收集45例肾透明细胞癌患者肿瘤组织与正常肾组织样本,通过microarray技术测定基因表达水平,比较肿瘤组织与正常组织的表达差异。
设计收集45例肾透明细胞癌患者肿瘤组织与正常肾组织样本,通过microarray技术测定基因表达水平,比较肿瘤组织与正常组织的表达差异。
摘要Systematic somatic mutation screening of 4000 genes in human clear cell renal cell carcinoma. Information on corresponding somatic mutations in each sample can be found at http://www.sanger.ac.uk/genetics/CGP/Studies/. These samples were run at a different facility than VARI - scmmlab.com
-
19 GSE274774 对肾透明细胞癌组织与正常肾组织进行比较,分别在体内灌注状态和术后缺血状态下采集样本,进行RNA测序,分析两组间及不同时间点的差异。
设计对肾透明细胞癌组织与正常肾组织进行比较,分别在体内灌注状态和术后缺血状态下采集样本,进行RNA测序,分析两组间及不同时间点的差异。
摘要Human isotopic tracer studies are fast becoming the gold standard model to study cancer metabolism in vivo. Analysed tissues are typically retrieved after surgical resection, which exposes them to a variable extent of warm ischaemia. Although standardised protocols are emerging, the effects of sampling conditions on the tissue metabolome remain understudied. Here, we perform a 13C-glucose study coupled with metabolomic, transcriptomic, and proteomic profiling in patients with clear cell renal cell carcinoma (ccRCC) to assess the metabolic profile of tissues sampled intraoperatively, when blood supply is intact, versus post-surgical resection, which exposes the tissue to ischaemia. We show that ischaemia significantly affects the metabolic landscape of ccRCC, masking some critical features, such as suppressed gluconeogenesis. Furthermore, in orthotopic ccRCC-derived xenografts, we identified that prolonged exposure to ischaemia disrupts the tissue metabolome stability. Therefore, minimising tissue ischaemia is pivotal in accurately profiling cancer metabolism in these important and resource-intense patient studies.
-
20 GSE117230 对肾透明细胞癌(ccRCC)患者与健康对照捐赠者的肿瘤浸润淋巴细胞(TIL)、正常组织浸润免疫细胞(TIIC)、外周血单个核细胞(PBMC)及匹配的健康对照外周血淋巴细胞进行基因表达微阵列分析,比较不同来源CD8+ T细胞和CD19+ B细胞在ccRCC患者与健康个体间的转录特征差异。
设计对肾透明细胞癌(ccRCC)患者与健康对照捐赠者的肿瘤浸润淋巴细胞(TIL)、正常组织浸润免疫细胞(TIIC)、外周血单个核细胞(PBMC)及匹配的健康对照外周血淋巴细胞进行基因表达微阵列分析,比较不同来源CD8+ T细胞和CD19+ B细胞在ccRCC患者与健康个体间的转录特征差异。
摘要Tumor infiltrating lymphocytes are widely associated with positive outcomes, but are still markers of a systemic failed immune response against unresolved cancer. Cancer immunotherapies can reverse their tolerance phenotypes, while preserving tumor-reactivity and neoantigen-specificity shared with circulating immune cells. We performed comprehensive transcriptomic analyses to identify gene signatures common to circulating and tumor infiltrating lymphocytes in the context of clear cell renal cell carcinoma. Modulated genes also associated with disease outcome were validated in other cancer types. Using bioinformatics we identified practical diagnostic markers and actionable targets of the failed immune response. On circulating lymphocytes, three genes could efficiently stratify patients from healthy control donors. From their associations with resistance to cancer immunotherapies as well as viral and bacterial infections, we have uncovered not only pan-cancer, but pan-pathology failed immune response gene signatures.
-
21 GSE47032 对肾透明细胞癌(ccRCC)肿瘤组织与匹配的非肿瘤肾组织进行全基因组范围的基因表达和剪接事件分析,采用Affymetrix Exon Array平台检测总RNA,比较肿瘤与非肿瘤组织的差异表达基因及外显子跳接情况。
设计对肾透明细胞癌(ccRCC)肿瘤组织与匹配的非肿瘤肾组织进行全基因组范围的基因表达和剪接事件分析,采用Affymetrix Exon Array平台检测总RNA,比较肿瘤与非肿瘤组织的差异表达基因及外显子跳接情况。
摘要In this study we performed a genome wide analysis of the entire complement of mRNAs in clear cell renal cell carcinomas (ccRCC) by means of the Affymetrix Exon Array platform. The analyses were performed both at gene and exon level. Under our parameters over 2,000 genes resulted differentially expressed, and about 250 genes resulted alternative spliced showing differential inclusion of specific cassette exons comparing tumor and non tumoral tissues.
-
22 GSE40912 对18例肾透明细胞癌肿瘤组织和11例非肿瘤相邻匹配组织进行微阵列分析,使用4k探针微阵列检测内含子长非编码RNA(lncRNA)表达。此外,17例肾癌样本(14例透明细胞,2例乳头状,1例色素性)被分为四个池,采用44k探针微阵列进行分析。研究通过比较肾癌与非肿瘤样本的lncRNA表达差异,识别出29个差异表达的内含子lncRNA,并进一步分析其与患者五年生存率的显著相关性。
设计对18例肾透明细胞癌肿瘤组织和11例非肿瘤相邻匹配组织进行微阵列分析,使用4k探针微阵列检测内含子长非编码RNA(lncRNA)表达。此外,17例肾癌样本(14例透明细胞,2例乳头状,1例色素性)被分为四个池,采用44k探针微阵列进行分析。研究通过比较肾癌与非肿瘤样本的lncRNA表达差异,识别出29个差异表达的内含子lncRNA,并进一步分析其与患者五年生存率的显著相关性。
摘要Intronic and intergenic long noncoding RNAs (lncRNAs) are emerging gene expression regulators. The molecular pathogenesis of renal cell carcinoma (RCC) is still poorly understood, and in particular, limited studies are available for intronic lncRNAs expressed in RCC. Microarray experiments were performed with two different custom-designed arrays enriched with probes for lncRNAs mapping to intronic genomic regions. Samples from 18 primary clear cell RCC tumors and 11 nontumor adjacent matched tissues were analyzed with 4k-probes microarrays. Oligoarrays with 44k-probes were used to interrogate 17 RCC samples (14 clear cell, 2 papillary, 1 chromophobe subtypes) split into four pools. Meta-analyses were performed by taking the genomic coordinates of the RCC-expressed lncRNAs, and cross-referencing them with microarray expression data from three additional human tissues (normal liver, prostate tumor and kidney nontumor samples), and with large-scale public data for epigenetic regulatory marks and for evolutionarily conserved sequences. A signature of 29 intronic lncRNAs differentially expressed between RCC and nontumor samples was obtained (false discovery rate (FDR) <5%). An additional signature of 26 intronic lncRNAs significantly correlated with the RCC five-year patient survival outcome was identified (FDR <5%, p-value ≤0.01). We identified 4303 intronic antisense lncRNAs expressed in RCC, of which 25% were cis correlated (r >|0.6|) with the expression of the mRNA in the same locus across three human tissues. Gene Ontology (GO) analysis of those loci pointed to ‘regulation of biological processes’ as the main enriched category. A module map analysis of all expressed protein-coding genes in RCC that had a significant (r ≥|0.8|) trans correlation with the 20% most abundant lncRNAs identified 35 relevant (p <0.05) GO sets. In addition, we determined that 60% of these lncRNAs are evolutionarily conserved. At the genomic loci containing the intronic RCC-expressed lncRNAs, a strong association (p <0.001) was found between their transcription start sites and genomic marks such as CpG islands and histones methylation and acetylation. Intronic antisense lncRNAs are widely expressed in RCC tumors. Some of them are significantly altered in RCC in comparison with nontumor samples. The majority of these lncRNAs is evolutionarily conserved and possibly modulated by epigenetic modifications. Our data suggest that these RCC lncRNAs may contribute to the complex network of regulatory RNAs playing a role in renal cell malignant transformation.
-
23 GSE76351 对50至75岁患者的肾组织(正常与肿瘤)进行基因表达分析,采用Affymetrix Human Gene 1.1 ST微阵列平台,比较肿瘤与正常组织的基因表达差异。
设计对50至75岁患者的肾组织(正常与肿瘤)进行基因表达分析,采用Affymetrix Human Gene 1.1 ST微阵列平台,比较肿瘤与正常组织的基因表达差异。
摘要Renal cell carcinoma (RCC) is one of the most widespread solid kidney tumors – it represents 90% of all malignant kidney tumors. Clear-cell RCC is the most widespread type of RCC. It is characterized by 3-rd chromosome rearrangements, VHL inactivation due to mutations or promoter hypermethylation, 5p amplification, and mutations in KDM6A/UTX, SETD2, KDM5C/JARID1C and MLL2 genes. Molecular profile of ccRCC was characterized in a number of research papers using high-throughput platforms (microarray SNP-profiling, RNA-seq, whole exome and whole genome sequencing). Nevertheless, differences of observed mutations and gene expression levels among different populations suggest that causes and mechanism of the disease can also vary. In order to obtain such information about Western Russian population we have performed DNA resequencing and microarray expression profiling, and then integrated this data in a single dataset. We then analyzed DNA mutations and gene expression level simultaneously using standard molecular data analysis pipelines (gene set enrichment analysis, casual gene network generation, principle component analysis).
-
24 GSE82122 采集肾透明细胞癌患者及正常样本的肾组织进行RNA测序,比较配对样本的转录组数据差异。样本采用福尔马林固定石蜡包埋(FFPE)保存,使用miRNeasy FFPE试剂盒提取总RNA,通过Illumina HiSeq 2500平台进行RNA-Seq分析,测序材料为polyA RNA。研究包含24个GSM样本,每个患者提供癌变(ccRCC)和正常组织样本,用于生物标志物开发的转录组数据对比。
设计采集肾透明细胞癌患者及正常样本的肾组织进行RNA测序,比较配对样本的转录组数据差异。样本采用福尔马林固定石蜡包埋(FFPE)保存,使用miRNeasy FFPE试剂盒提取总RNA,通过Illumina HiSeq 2500平台进行RNA-Seq分析,测序材料为polyA RNA。研究包含24个GSM样本,每个患者提供癌变(ccRCC)和正常组织样本,用于生物标志物开发的转录组数据对比。
摘要This dataset complements GSE76207. Formalin-fixed, paraffin-embedded (FFPE) tissues are an underused resource for molecular analyses. This proof of concept study aimed to compare RNAseq results from FFPE biopsies (Eikrem et al., PLoS One. 2016 Feb 22;11(2):e0149743. doi: 10.1371/journal.pone.0149743. eCollection 2016. PMID: 26901863) with FFPE confirmation dataset from clear cell renal cell carcinoma (ccRCC) patients. Core biopsies were obtained with a 16g needle from 16 patients undergoing partial or full nephrectomy. The RNA sequencing libraries were generated applying the new Illumina TruSeq® Access library preparation protocol. The goal of the study is to compare the discovery and the confirmation data and to assess the utilization of the data for ccRCC biomarker development.
-
26 GSE102101 对10对患者匹配的正常肾组织与ccRCC肿瘤组织进行RNA测序,比较其转录组与表观遗传修饰(H3K27ac、H3K4me1、H3K4me3)差异。每对样本包含相邻正常肾组织和ccRCC肿瘤组织,共20个GSM样本,按总单位数与组数估计每组10个独立样本。
设计对10对患者匹配的正常肾组织与ccRCC肿瘤组织进行RNA测序,比较其转录组与表观遗传修饰(H3K27ac、H3K4me1、H3K4me3)差异。每对样本包含相邻正常肾组织和ccRCC肿瘤组织,共20个GSM样本,按总单位数与组数估计每组10个独立样本。
摘要VHL loss is the most common genetic alteration event in ccRCC, but its effect on epigenetic landscape has not been elucidated previously. We describe the genome-wide cis-regulatory landscapes of VHL-deficient ccRCC tumors by comparing the epigenetic changes in terms of histone modifications (H3K27ac, H3K4me1, H3K4me3) with the transcriptomics profiles in 10 pairs of normal kidney and ccRCC tissues.
-
27 GSE217386 对10对肾透明细胞癌组织及其对应的相邻非肿瘤组织进行mRNA表达谱分析,采用RNA测序技术检测总RNA表达水平,比较肿瘤组织与正常组织的基因表达差异。
设计对10对肾透明细胞癌组织及其对应的相邻非肿瘤组织进行mRNA表达谱分析,采用RNA测序技术检测总RNA表达水平,比较肿瘤组织与正常组织的基因表达差异。
摘要DNA helicases are essential to genomic stability by regulating DNA metabolisms and their loss-of-function mutations lead to genomic instability and predisposition to cancer. Paradoxically, overexpression of DNA helicases is observed in several cancers, but systemic analyses of their alterations and biological or clinical implications in human cancer have not been reported. Here we analyzed genomic and molecular alterations in 12 important DNA helicases across 33 cancer types from the TCGA dataset to provide an overview of their aberrations. Significant expression heterogeneity of 12 DNA helicases was observed. We calculated DNA helicase score (DHS) based on their expression, and categorized tumors into high, low and intermediate subtypes. High DHS subtypes were robustly associated with stemness, proliferation, hyperactivated oncogenic signaling, longer telomeres, total mutation burden, copy number alterations (CNAs) and shorter survival. Importantly, tumors with high DHSs exhibited stronger expression of alternative end-join (alt-EJ) factors, indicative of sensitivity to chemo- and radio-therapies. Several drugs are identified to inhibit DNA helicases, with the Auror A kinase inhibitor Danusertib as the strongest candidate. The aberrant expression of DNA helicases was associated with CNAs, DNA methylation and m6A regulators. Our findings thus reveal widespread dysregulation of DNA helicases and their broad connection with featured oncogenic aberrations across human cancer. The close association of DHS with the alt-EJ pathway and cellular proliferation suggests that tumors with higher DHS are sensitive to chemotherapy and radiotherapy; The Auror A kinase inhibitor Danusertib may also inhibit DNA helicases. These findings thus contribute to DNA helicase-based cancer therapy.
-
28 GSE252600 对肾透明细胞癌患者肿瘤组织与相邻正常组织进行RNA测序,比较两者的基因表达差异。研究采用9对肿瘤-正常组织样本,通过mRNA测序分析APOL1表达水平,并探究其在癌细胞转移特性中的作用。
设计对肾透明细胞癌患者肿瘤组织与相邻正常组织进行RNA测序,比较两者的基因表达差异。研究采用9对肿瘤-正常组织样本,通过mRNA测序分析APOL1表达水平,并探究其在癌细胞转移特性中的作用。
摘要The 5-year survival rate of kidney cancer drops dramatically from 93% to 15% when it is metastatic. Metastasis constitutes for 30% of kidney cancer cases, in which clear cell renal cell carcinoma (ccRCC) is the most prominent subtype. By sequencing mRNA of ccRCC patient samples, we found that apolipoprotein L1 (APOL1) was highly expressed in tumors compared to their adjacent normal tissues. This gene has been previously identified in a large body of kidney disease research and was reported as a potential prognosis marker in many types of cancers. However, the molecular function of APOL1 in ccRCC, especially in metastasis, remained unknown. In this study, we modulated the expression of APOL1 in various renal cancer cell lines and analyzed their proliferative, migratory, and invasive properties. Strikingly, APOL1 overexpression suppressed ccRCC metastasis both in vitro and in vivo. We then explored the mechanism by which APOL1 alleviated ccRCC malignant progression by investigating its downstream pathways. APOL1 overexpression diminished the activity of focal adhesive molecules, Akt signaling pathways, and EMT processes. Furthermore, in the upstream, we discovered that miR-30a-3p could inhibit APOL1 expression. In conclusion, our study revealed that APOL1 play a role as a tumor suppressor in ccRCC and inhibit metastasis, which may provide novel potential therapeutic approaches for ccRCC patients.
-
29 GSE39364 对15例肾透明细胞癌组织与11例正常肾皮质混合样本进行基因表达分析,采用cDNA微阵列检测技术比较两者基因表达差异。
设计对15例肾透明细胞癌组织与11例正常肾皮质混合样本进行基因表达分析,采用cDNA微阵列检测技术比较两者基因表达差异。
摘要In order to clarify the molecular mechanism involved in renal carcinogenesis, and identify molecular targets for diagnosis and treatment, we analyzed genome-wide gene expression profiles of 15 surgical specimens of clear cell renal cell carcinoma (RCC), compared to normal renal cortex, using a combination of laser microbeam microdissection (LMM) with a cDNA microarray representing 27,648 genes.
-
30 GSE12606 对三例肾透明细胞癌患者的原发肿瘤、自体正常组织及转移灶样本进行分析,其中两例采用质谱法检测 HLA 配体组,三例通过寡核苷酸微阵列分析转录组。样本采集后液氮速冻保存,检测对象为总 RNA,比较原发肿瘤与转移灶、原发肿瘤与正常组织、转移灶与正常组织间的差异。
设计对三例肾透明细胞癌患者的原发肿瘤、自体正常组织及转移灶样本进行分析,其中两例采用质谱法检测 HLA 配体组,三例通过寡核苷酸微阵列分析转录组。样本采集后液氮速冻保存,检测对象为总 RNA,比较原发肿瘤与转移灶、原发肿瘤与正常组织、转移灶与正常组织间的差异。
摘要In recent years, several approaches have been taken in the peptide-based immunotherapy of metastatic renal cell carcinoma (RCC), although little is known about HLA presentation on metastases compared to primary tumor and normal tissue of RCC. In this study we compared primary tumor, normal tissue and metastases with the aim of identifying similarities and differences between these tissues. We performed this comparison for two RCC patients on the level of the HLA ligandome using mass spectrometry and for three patients on the level of the transcriptome using oligonucleotide microarrays. The quantitative results show that primary tumor is more similar to metastasis than to normal tissue, both on the level of HLA ligand presentation and mRNA. We were able to characterize a total of 142 peptides in the qualitative analysis of HLA-presented peptides. Six of them were significantly overpresented on metastasis, among them a peptide derived from CD151; fourteen were overpresented on both primary tumor and metastasis compared to normal tissue, among them an HLA ligand derived from tumor protein p53. Thus, we could demonstrate that peptide-based immunotherapy might affect tumor as well as metastasis of RCC, but not healthy kidney tissue. Furthermore we were able to identify several peptides derived from tumor-associated antigens that are suitable for vaccination of metastatic RCC.
-
31 GSE150833 对5例肾透明细胞癌患者与5例健康对照的血浆样本进行非编码RNA微阵列表达分析,比较两组间差异表达的长链非编码RNA和mRNA。未对样本进行特殊处理,仅通过离心获取血浆并提取总RNA用于微阵列检测。
设计对5例肾透明细胞癌患者与5例健康对照的血浆样本进行非编码RNA微阵列表达分析,比较两组间差异表达的长链非编码RNA和mRNA。未对样本进行特殊处理,仅通过离心获取血浆并提取总RNA用于微阵列检测。
摘要Objective: The diagnostic roles of long non-coding RNAs (lncRNAs) in clear cell renal cell carcinoma (ccRCC) are still not well defined. We aimed to identify differentially expressed lncRNAs and mRNAs in plasma of ccRCC patients and health controls systematically. Methods: Expression profile of lncRNAs and mRNAs in plasma from ccRCC patients and healthy controls was analyzed by microarray assay. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway based approaches were used to investigate biological functions and signaling pathways affected by the differentially expressed mRNAs. SOCS2-AS1 was selected for validation using Real-Time PCR. The differentially expressed genes were further compared with E-MTAB-1830 datasets by Venn and NetworkAnalyst website. The expression level and overall survival (OS) of differentially expressed mRNAs were analyzed in GEPIA and ULCAN website. Results: Compared with healthy controls, a total of 3,664 differentially expressed lncRNAs were revealed by heatmap and volcano-plot, including up-regulation in 1,511 and down-regulation in 2,153 (fold change ≥ 2 and P < 0.05), respectively. And differential expression was noticed in 2,268 mRNAs, including up-regulation in 932 mRNAs and down-regulation in 1,336 mRNAs, respectively (fold change ≥ 2 and P < 0.05). Pathways analysis based on deregulated mRNAs were mainly involved in melanogenesis and Hippo signaling pathway (P < 0.05). The expression of SOCS2-AS1 was down in ccRCC plasma and tissues, as well as in cell lines, which was the same as the results of lncRNA microarray. Compared with the E-MTAB-1830 gene expression profiles, we identified 18 lncRNAs, and 87 mRNAs were differently expressed in both plasma and neoplastic tissues of ccRCC. Ten mRNAs (EPB41L4B, CCND1, GGT1, CGNL1, CYSLTR1, PLAUR, UGT3A1, PROM2, MUC12, and PCK1) were correlated with the overall survival (OS) rate in ccRCC patients based on the GEPIA and ULCAN website.Conclusions: We first reported differentially expressed lncRNAs in ccRCC patient and healthy control systemically. Combined with the published dataset, we identified several differentially expressed lncRNAs and mRNAs which might to be diagnostic or prognostic markers. The biological functions of those lncRNAs and mRNAs should be further validated. Taken together, this study provided the basis for future treatment of ccRCC and novel insights into cancer biology.
-
32 GSE346548 对5例清亮细胞肾细胞癌肿瘤组织及5例相邻正常肾组织进行全转录组RNA测序,比较肿瘤与正常组织的mRNA、lncRNA和circRNA表达特征。所有样本均来自人类,采用RNA-Seq策略检测总RNA,通过冷冻样本提取RNA并进行文库构建,最终获得10个测序库。
设计对5例清亮细胞肾细胞癌肿瘤组织及5例相邻正常肾组织进行全转录组RNA测序,比较肿瘤与正常组织的mRNA、lncRNA和circRNA表达特征。所有样本均来自人类,采用RNA-Seq策略检测总RNA,通过冷冻样本提取RNA并进行文库构建,最终获得10个测序库。
摘要Renal cell carcinoma (RCC) is among the most common urological malignancies, yet the transcriptomic landscape underlying its pathogenesis remains incompletely characterized, particularly for non-coding regions that may harbor functional non-canonical open reading frames (ncORFs). Here we performed whole-transcriptome RNA-seq on 5 clear cell RCC tumor tissues and 5 adjacent normal kidney tissues to systematically profile mRNA, lncRNA, and circRNA expression. This dataset serves as the transcriptomic layer of an integrative multi-omics study aimed at identifying dysregulated ncORF-encoded micropeptides in RCC, with lncRNAs representing a predominant source of tumor-associated cryptic peptides. The data provide a reference for translational activity assessment when combined with matchedribosome profiling and immunopeptidomics datasets.
-
33 GSE96574 将5对肾透明细胞癌组织与相邻非肿瘤组织进行比较,使用整合lncRNA和mRNA的微阵列检测其基因表达谱。研究对象为人类肾透明细胞癌及相邻非肿瘤组织,样本按5对混池,检测方式为微阵列分析,包括背景校正、空间趋势校正及quantile归一化,比较癌组织与对应正常组织的表达差异。
设计将5对肾透明细胞癌组织与相邻非肿瘤组织进行比较,使用整合lncRNA和mRNA的微阵列检测其基因表达谱。研究对象为人类肾透明细胞癌及相邻非肿瘤组织,样本按5对混池,检测方式为微阵列分析,包括背景校正、空间趋势校正及quantile归一化,比较癌组织与对应正常组织的表达差异。
摘要Five matched clear cell renal cell carcinoma and normal tissues were used for microarray.
-
34 GSE168845 对4例肾透明细胞癌(ccRCC)患者及其配对的非癌变肾组织(NRT)样本进行基因表达分析,使用SurePrint G3 Human GE 8×60K微阵列平台检测总RNA,比较癌变组织与正常组织的基因表达差异。研究共包含8个样本,无生物重复。
设计对4例肾透明细胞癌(ccRCC)患者及其配对的非癌变肾组织(NRT)样本进行基因表达分析,使用SurePrint G3 Human GE 8×60K微阵列平台检测总RNA,比较癌变组织与正常组织的基因表达差异。研究共包含8个样本,无生物重复。
摘要Clear cell renal cell carcinoma (ccRCC), is the most common subtype of kidney tumors and characterised by the highest mortality rates among the genitourinary cancers. The currently used models for predicting patient outcome, are based on clinicopathological features only, however patients with similar measures can still have divergent outcomes. This study aimed at identification of novel prognostic DNA methylation biomarkers to aid in predicting patient survival. As DNA methylation in the most cases is related to alteration of gene expression, firstly, SurePrint G3 Human GE 8×60K Microarrays were used for gene expression profiling in 4 ccRCC tissues and paired non-cancerous renal tissue (NRT) samples. The DNA methylation status of four down-regulated genes were evaluated in 123 ccRCC and 45 NRT samples by means of methylation specific PCR (MSP). Microarray-based transcriptome comparison of 4 ccRCC and 4 NRT samples identified 3942 genes, that were significantly deregulated (P < 0.050) with absolute fold change (FC) value of ≥2. A half of these genes (N = 1958) were down-regulated and four of such genes with moderate-to-high alteration were selected for the further DNA methylation analysis. DNA hypermethylation of all selected genes were cancer specific (P<0.050) with the frequency in tumour tissues ranging from 18 to 42%. The methylated status of at lest one gene showed significant associations with larger tumor size, higher Fuhrman and WHO/ISUP grades as well as the presence of tumor intravascular invasion and necrosis. Moreover, the methylated status of the panel of tree genes was highly predictive for poorer overall survival and outperformed the prognostic value of tumor stage and tumor necrosis. In conclusion, the three-gene DNA methylation biomarker panel predicts outcome of patients with ccRCC and might be used to improve current prognostic models.
-
35 GSE100666 对肾透明细胞癌(ccRCC)肿瘤组织及其对应的邻近正常肾组织进行微阵列表达分析,比较不同阶段(stage 1/2/3)ccRCC组织与相应正常组织的基因表达差异。研究对象为人类男性ccRCC肿瘤组织及邻近正常肾组织,按肿瘤阶段分组,每组包含1个肿瘤样本与1个正常样本,共3组6个样本。检测采用微阵列平台,数据经中位数缩放归一化处理,通过log2比值和p值呈现配对样本间的差异。
设计对肾透明细胞癌(ccRCC)肿瘤组织及其对应的邻近正常肾组织进行微阵列表达分析,比较不同阶段(stage 1/2/3)ccRCC组织与相应正常组织的基因表达差异。研究对象为人类男性ccRCC肿瘤组织及邻近正常肾组织,按肿瘤阶段分组,每组包含1个肿瘤样本与1个正常样本,共3组6个样本。检测采用微阵列平台,数据经中位数缩放归一化处理,通过log2比值和p值呈现配对样本间的差异。
摘要Renal cell carcinoma (RCC) is the most common and lethal cancer of the adult kidney. Its incidence is increasing and outcomes remain poor. Accurate discrimination of RCC patients with poor prognosis was very important for the appropriate and effective patient management. ccRCC originated from dysregulation of different gene expression. To screen novel prognosis markers, a dysregulated mRNA expression profile was identified by microarray in some pairs of different stages ccRCC.
-
36 GSE69197 对肾透明细胞癌(ccRCC)患者与正常肾组织的RNA测序样本进行比较分析,采集冷冻肾组织样本(N=6)并分组为正常肾(Uninvolved Kidney)和ccRCC,采用RNA-Seq策略检测总RNA表达特征,比较两组组织的基因表达差异。
设计对肾透明细胞癌(ccRCC)患者与正常肾组织的RNA测序样本进行比较分析,采集冷冻肾组织样本(N=6)并分组为正常肾(Uninvolved Kidney)和ccRCC,采用RNA-Seq策略检测总RNA表达特征,比较两组组织的基因表达差异。
摘要To address the need to study frozen clinical specimens using next-generation RNA, DNA, chromatin immunoprecipitation (ChIP) sequencing and protein analyses, we developed a biobank work flow to prospectively collect biospecimens from patients with renal cell carcinoma (RCC). We describe our standard operating procedures and work flow to annotate pathologic results and clinical outcomes. We report quality control outcomes, nucleic acid yields of our RCC submissions (N=16) to The Cancer Genome Atlas (TCGA) project, as well as newer discovery platforms by describing mass spectrometry analysis of albumin oxidation in plasma and 6 ChIP sequencing libraries generated from nephrectomy specimens after histone H3 lysine 36 trimethylation (H3K36me3) immunoprecipitation. From June 1, 2010, through January 1, 2013, we enrolled 328 patients with RCC. Our mean (SD) TCGA RNA integrity numbers (RINs) were 8.1 (0.8) for papillary RCC, with a 12.5% overall rate of sample disqualification for RIN <7. Banked plasma had significantly less albumin oxidation (by mass spectrometry analysis) than plasma kept at 25°C (P<.001). For ChIP sequencing, the FastQC score for average read quality was at least 30 for 91-95% of paired-end reads. In parallel, we analyzed frozen tissue by RNA sequencing and after genome alignments, only 0.2-0.4% of total reads failed the default quality check steps of Bowtie2, which was comparable to the disqualification ratio (0.1%) of the 786-O RCC cell line, prepared under optimal RNA isolation conditions. The overall correlation coefficients for gene expression between the Mayo Clinic vs. TCGA tissues ranged from 0.75 to 0.82. These data support the generation of high-quality nucleic acids for genomic analyses from banked RCC. Importantly, the protocol does not interfere with routine clinical care. Collections over defined time points during disease treatment further enhance collaborative efforts to integrate genomic information with outcomes.

课题合作 · 扫码加微信
bioinformaticsboy